Composition
Chair:
Vice chair:
Members:
Thorsten Simon (Germany), Shifra Ash (Israel), Mark Gaze (UK), Giuseppe Barone (UK), Jakob Stenman (Sweden), Alba Rubio (Spain), Lynda Attalah Habiba (France)
Aims
The SIOPEN CTC was established in June 2020, with the aim of facilitating the opening and running SIOPEN clinical trials.
The objectives of the CTC include:
- To create and maintain a database of all SIOPEN clinical trials
- To regularly review the progress of all SIOPEN clinical trials, from concept through to data publication
- To facilitate the timely opening of studies
- To Facilitate the timely publication of data
- To provide advice and support when there are obstacles to progress
- To share progress about SIOPEN clinical trials
- To develop SOPs for SIOPEN clinical trial conduct
If you have a new study concept or proposal, then please let us know details and we will be pleased to offer our support. Please complete this form.
You can find hereunder the list of the SIOPEN clinical trials (to get more details please go to the clinical trial page here):
- SIOPEN High Risk Neuroblastoma Study 2 (HR-2)
- SIOPEN Low and Intermediate Risk Neuroblastoma European Study (LINES)
- VERITAS (Trial Evaluating and Comparing Two Intensification Treatment Strategies for Metastatic Neuroblastoma Patients With a Poor Response to Induction Chemotherapy
- A randomised phase IIb trial of BEvACizumab added to Temozolomide ± IrinOtecan for children with refractory/relapsed Neuroblastoma (The BEACON trial)
- Spinal cord compression
- A Phase I study of 131-1 mIBG followed by Nivolumab and Dinutuximab beta Antibody in children with relapsed/refractory Neuroblastoma. (The MINIVAN trial)
- Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma (RIST-rNB-2011)
- Prospective multicentre clinical trial for risk estimation and treatment stratification in low and intermediate risk neuroblastoma patients (NB2015-LR)
